Tianmei Biotech Successfully Listed on Nasdaq Capital Market
Industry: Health Biotechnology
Listing Date: 2021, Nasdaq Capital Market, USA
Funding Amount: 27.85 million USD
Partners: Tiger Brokers
Yangkang Asset, in partnership with Tiger Brokers, successfully assisted Tianmei Biotech (BON) in listing on the Nasdaq Capital Market in the United States, raising 27.85 million USD and becoming a prominent representative of Asia’s health biotech sector entering the international market.
Tianmei Biotech focuses on the research and production of health products, committed to providing natural, safe, and efficient biotech solutions, covering nutritional supplements, functional foods, and personal health care. Through this listing, Tianmei Biotech plans to accelerate product innovation, expand global sales channels, and deepen cooperation with international research institutions.
With this Nasdaq listing, Tianmei Biotech further consolidates its market position and plans to accelerate product innovation and R&D, expand global sales channels, and deepen cooperation with international research institutions to promote the launch of more high-quality health products. Additionally, Tianmei Biotech will actively enhance its brand’s international influence, further expanding into North America and other overseas markets, aiming to become a leading global health biotech enterprise.